Last reviewed · How we verify

NCT06073340: STIM-RAD

The Longitudinal Study of Stimulant Use Disorder

Terminated Last updated 8 April 2025
What this trial tests

trial in Stimulant Use in 72 participants. Terminated before completion.

Timeline
16 November 2023
Primary endpoint
31 March 2025
31 March 2025

Quick facts

Lead sponsorUniversity of Texas Southwestern Medical Center
StatusTerminated
Study typeOBSERVATIONAL
Enrollment72
Start date16 November 2023
Primary completion31 March 2025
Estimated completion31 March 2025
Sites1 location across United States

Conditions studied

Sponsor

University of Texas Southwestern Medical Center

Who can join

Adults 18 to 85, any sex, with Stimulant Use or Stimulant-Related Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research is a 5-year observational, longitudinal registry study with no treatment or medication provided as part of participation. Individuals with current or lifetime stimulant use disorder, in addition to healthy control individuals, may be eligible to participate in this study. A variety of assessments and tasks including Magnetic Resonance Imaging (MRI), Electroencephalography (EEG), blood draws, urine drug screens, and both self-report and clinician-rated assessments will be used to assess biomarkers in this population. This study has a visit schedule of four in-person visits and eight remote visits per year.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Stimulant Use

Currently open trials in the same condition.

Other University of Texas Southwestern Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06073340.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing